NurExone Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Completed the first tranche of a non-brokered private placement offering of units for gross proceeds…
Completed the first tranche of a non-brokered private placement offering of units for gross proceeds…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development…
Kenny has proven track record of driving growth at companies within the healthcare space and…
Kenny has proven track record of driving growth at companies within the healthcare space and…
MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company…
MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company…
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy,…
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy,…
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology…
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from…
New preclinical data characterizing NE3107 mechanism of action featured in oral presentation Phamacokinetic data from…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company…
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) — Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company…
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading,…